30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
Approximately 30% of patients with hepatocellular carcinoma are due to abnormalities in the FGF19- FGFR4 signaling pathway. BLU-554 can inhibit FGFR4 with high specificity to treat hepatocellular carcinoma caused by abnormal FGF19-FGFR4 signaling pathway. (BLU-554, a novel targeted agent in clinical trials, targets FGFR4 (paired with FGF19) in patients with advanced hepatocellular carcinoma in the FGF19-amplified or high-expression subtype.)